Company Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Prothena Corporation plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
20.56 ^USD	0.00%		-2.10%	-43.42%

Mar. 04	Prothena Names David Ford as Chief People Officer	MT
Mar. 04	Prothena Appoints David Ford to Newly Created Chief People Officer	CI

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Companyâs pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimerâs disease, Parkinsonâs disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinsonâs disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimerâs disease.

Number of employees: 173

USD in Million	2022	Weight	2023	Weight	Delta
Collaboration 99.9 %	14	25.7 %	91	99.9 %	+559.11%
License and Intellectual Property 0.1 %	40	74.3 %	0	0.1 %	-99.88%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	54	100.0 %	91	100.0 %	+69.41%

Managers	Title	Age	Since
Gene Kinney CEO	Chief Executive Officer	55	12-11-30
Tran Nguyen DFI	Director of Finance/CFO	50	13-02-28
Wagner M. Zago CTO	Chief Tech/Sci/R&D Officer	51	11-12-31
Brandon Smith COO	Chief Operating Officer	50	20-03-02
Hideki Garren CTO	Chief Tech/Sci/R&D Officer	60	21-04-04
Randy Fawcett IRO	Public Communications Contact	-	-
Michael J. Malecek LAW	General Counsel	58	19-06-30
Yvonne M. Tchrakian SEC	Corporate Secretary	-	13-12-31
Karin Walker AUD	Comptroller/Controller/Auditor	60	13-05-19
Carol Karp LAW	General Counsel	71	16-12-14

Members of the board	Title	Age	Since
Richard Collier BRD	Director/Board Member	70	12-12-19
Gene Kinney CEO	Chief Executive Officer	55	12-11-30
Helen Kim BRD	Director/Board Member	61	22-07-31
Dennis Selkoe BRD	Director/Board Member	80	13-07-21
Daniel Welch BRD	Director/Board Member	66	Feb. 20
Shane Cooke BRD	Director/Board Member	61	12-12-19
Karl Härfstrand BRD	Director/Board Member	66	15-06-28
Lars Ekman CHM	Chairman	74	12-12-19
Oleg Nodelman BRD	Director/Board Member	47	19-12-02
Paula Cobb BRD	Director/Board Member	51	19-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	53,720,455	47,039,852 ( 87.56 %)	0	87.56 %

Name	Equities	%	Valuation
EcoR1 Capital, LLC 21.56 %	11,584,280	21.56 %	287 M $
Fidelity Management & Research Co. LLC 14.98 %	8,049,796	14.98 %	199 M $
Woodford Investment Management Ltd. 13.87 %	7,448,790	13.87 %	185 M $
T. Rowe Price International Ltd. 7.888 %	4,237,351	7.888 %	105 M $
BlackRock Advisors LLC 6.578 %	3,533,504	6.578 %	88 M $
William P Scully 6.520 %	3,502,481	6.520 %	87 M $
Todd W Fennell 5.848 %	3,141,459	5.848 %	78 M $
STATE STREET CORPORATION 5.135 %	2,758,564	5.135 %	68 M $
Wellington Management Co. LLP 4.829 %	2,594,102	4.829 %	64 M $
Janus Henderson Investors US LLC 3.790 %	2,035,984	3.790 %	50 M $

Prothena Corp. Plc

77 Sir John Rogersons Quay Grand Canal Docklands

2, Dublin

+353 1 236 2500

http://www.prothena.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.56 USD

Average target price

66.09 USD

Spread / Average Target

+221.45%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTHENA CORPORATION PLC	-43.42%	1.1B
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs